FULLERTON, Calif.–(Business Wire)–Dr. Jack Florin, one of Southern California’s preeminent Neurologists, announced today that Fullerton Neurology and Headache Center has introduced a new website to better showcase its full suite of services.
“We wanted to launch a digital platform that more accurately communicated our complete range of services and core competencies,” said Florin. “Our core competencies cover a broad range of services including Neurological Care, Multiple Sclerosis, Headaches, and Children’s Headache treatments, Neuromuscular Disorders and our Electrodiagnostic Laboratory as well as Clinical Trials.”
In addition Fullerton Neurology and Headache Center launched a new Facebook presence as well as a Twitter site to build the Center’s community outreach.
Read more about this article here.
Fullerton Neurology and Headache Center
Dr. Jack Florin, MD
Overall, about 60% of patients with epilepsy have a permanent remission, meaning no seizures on medication. About 25% are treatment-resistant. The remainder are not seizure-free but have good quality of life.
Childhood absence epilepsy (petit mal) can be controlled about 80% of the time.
About 70% of patients with juvenile myoclonic epilepsy are seizure-free. Most need lifelong treatment, but recent studies show that about 10% to 20% could stop medications after many years.
Poor prognostic factors are a young age at onset of seizures, more seizures at the start of treatment, and a higher number of drugs that a patient has failed.
A new and exciting development is the recognition of “autoimmune epilepsy,” which may be common in patients with treatment-resistant seizures and may respond to treatment other than antiepileptic drugs.
For more information visit our website http://www.fullertonneurocenter.com
Or give us a call at (714) 738-0800
Research presented in April 2014 at the American Academy of Neurology annual meeting identified 4 key genes that explain why some people have a higher and others a lower pain tolerance. Over 2700 people diagnosed with chronic pain were tested for certain genes. Nine percent had high pain tolerance, 46% moderate, and 45% low pain tolerance. The DRD1 gene variant was 33% more prevalent in the high pain tolerance group. The DR2 gene was 25% more common in patients with low pain tolerance. Two other genes also correlated. All participants were taking opioid pain medications. More studies are planned.
For more information, please contact us at
Phone (714) 738-0800
or via email
Visit our website
The results of a study in which we were a site of a drug, ofatumumab, an anti-B-cell antibody, were reported at the AAN meeting. The drug showed marked reduction in MRI lesions. Patients receiving the drug had less than 1 new brain lesion per year, whereas placebo group had 16 lesions. The drug is now entering phase III trials, the last step before applying for FDA approval to market it in the United States.
For more information visit our website at www.fullertonneurocenter.com
Also presented at the AAN annual meeting, a study of 67 people with asymptomatic 50% carotid artery stenosis and 60 people with vascular risk factors but without stenosis. Risk factors included diabetes, hypertension, high blood cholesterol, and coronary artery disease. The carotid stenosis group performed significantly worse on tests for motor and processing speed, learning, and memory. Language scores did not differ. Patients with 50% asymptomatic carotid artery stenosis generally are not advised to have surgery. This strategy may change.
For more information please contact us at
Phone (714) 738-0800
Or visit our website http://www.fullertonneurocenter.com